GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $4.27 $5.86 Friday, 19th Apr 2024 BCRX stock ended at $4.43. This is 1.56% less than the trading day before Thursday, 18th Apr 2024. During the day the stock fluctuated 7.49% from a day low at $4.27 to a day high of $4.59.
90 days $4.27 $6.35
52 weeks $4.27 $9.07

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
2024-02-07 $5.50 $5.54 $5.29 $5.30 2 552 807
2024-02-06 $5.09 $5.52 $5.02 $5.51 2 478 226
2024-02-05 $5.04 $5.15 $4.93 $5.14 1 914 777
2024-02-02 $5.25 $5.25 $4.95 $5.08 2 922 337
2024-02-01 $5.36 $5.39 $5.22 $5.28 1 943 051
2024-01-31 $5.50 $5.62 $5.30 $5.30 1 703 614
2024-01-30 $5.66 $5.66 $5.48 $5.50 1 946 514
2024-01-29 $5.42 $5.70 $5.25 $5.67 2 229 955
2024-01-26 $5.49 $5.62 $5.42 $5.44 1 768 126
2024-01-25 $5.43 $5.61 $5.38 $5.45 2 212 493
2024-01-24 $5.57 $5.59 $5.40 $5.40 2 062 939
2024-01-23 $5.74 $5.75 $5.36 $5.50 2 519 614
2024-01-22 $5.71 $5.84 $5.39 $5.62 3 995 656
2024-01-19 $5.75 $5.75 $5.60 $5.67 2 270 320
2024-01-18 $5.95 $5.97 $5.68 $5.76 2 243 835
2024-01-17 $5.97 $6.04 $5.88 $5.96 2 701 680
2024-01-16 $6.22 $6.22 $5.93 $6.09 2 876 774
2024-01-12 $6.51 $6.66 $6.23 $6.35 3 025 745
2024-01-11 $6.76 $6.84 $6.43 $6.47 4 058 639
2024-01-10 $7.54 $7.75 $6.75 $6.88 5 370 135
2024-01-09 $7.56 $7.69 $7.39 $7.44 4 449 142
2024-01-08 $6.30 $7.65 $6.12 $7.65 11 956 874
2024-01-05 $6.36 $6.37 $6.09 $6.09 2 561 684
2024-01-04 $6.05 $6.54 $6.05 $6.46 3 862 171
2024-01-03 $6.00 $6.05 $5.85 $6.00 2 677 711
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT